

UTILIZATION MANAGEMENT MEDICAL POLICY

POLICY: Parkinson's Disease – Onapgo Utilization Management Medical Policy

- Onapgo™ (apomorphine subcutaneous injection – Supernus)

REVIEW DATE: 03/25/2026

OVERVIEW

Onapgo, a dopaminergic agonist continuous subcutaneous infusion, is indicated for the treatment of motor fluctuations in adults with advanced **Parkinson's disease**.¹

Guidelines

The International Parkinson and Movement Disorder Society published an evidence-based review for treatment for motor symptoms of Parkinson's disease (2018); an update specific to motor fluctuations was published in 2025.^{2,3} In the 2025 update, continuous use of apomorphine was regarded as likely efficacious for treatment of motor fluctuations.

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Onapgo. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Onapgo as well as the monitoring required for adverse events and long-term efficacy, approval requires Onapgo to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Onapgo is recommended in those who meet the following criteria:

FDA-Approved Indication

-
- 1. Parkinson's Disease.** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):
 - A)** Patient is diagnosed with advanced Parkinson's disease; AND
 - B)** Patient is experiencing "off" episodes; AND
Note: Examples of "off" episodes include muscle stiffness, slow movements, or difficulty starting movements.
 - C)** Patient has tried an oral carbidopa/levodopa therapy and meets ONE of the following (i or ii):
 - i.** According to the prescriber, patient had significant intolerance; OR
 - ii.** According to the prescriber, patient had inadequate efficacy; AND
 - D)** Patient has previously tried or is currently receiving ONE other treatment for "off" episodes; AND
-

Note: Examples of treatment for “off” episodes include pramipexole, ropinirole, Neupro (rotigotine transdermal system), apomorphine, selegiline, rasagiline, Xadago (safinamide tablets), tolcapone, entacapone, Ongentys (opicapone capsules), Nourianz (istradefylline tablets), or amantadine.

E) The medication is prescribed by or in consultation with a neurologist.

Dosing. Approve up to 98 mg administered as a subcutaneous infusion every day.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Onapgo is not recommended in the following situations:

1. **Concurrent Use with a Serotonin 5-HT₃ Antagonist.** Administration of Onapgo in conjunction with a serotonin 5-HT₃ antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron) can result in extreme lowering of blood pressure and loss of consciousness and is considered an absolute contraindication.¹
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Onapgo™ subcutaneous injection [prescribing information]. Rockville, MD: Supernus; February 2025.
2. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Mov Disord.* 2018;33(8):1248-1266.
3. de Bie RMA, Katzenschlager R, Swinnen BEKS, et al. Update on treatments for Parkinson's Disease motor fluctuations – an International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. *Mov Disord.* 2025 May;40(5):776-794.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	05/28/2025
Selected Revision	Concurrent Use with a Serotonin 5-HT ₃ Antagonist was added under “Conditions Not Recommended for Approval”.	06/11/2025
Early Annual Revision	Policy Statement: In the statement “approval requires Onapgo to be prescribed by or in consultation with a physician who specializes in the condition being treated”, the preceding word “initial” was removed to clarify that all approvals (initial and reauthorization) require that Onapgo is prescribed by or in consultation with a specialist. Parkinson’s Disease: The list of examples of treatments for Parkinson’s disease off episodes was updated to remove cabergoline and to add Neupro (rotigotine transdermal system), apomorphine, Nourianz (istradefylline tablets), and amantadine.	03/25/2026